化学
克拉斯
计算生物学
癌症研究
突变
药物发现
结构-活动关系
体外
药理学
苯衍生物
作者
Dean P. Phillips,Phil B. Alper,Charles Y. Cho,Dmitry Borkin,Dong Han,Sarah E. Kochanek,Agnes Vidal-Biggart,Ananda Herath,Jitendra Gurjar,Wenshuo Lu,Casey J. N. Mathison,John M. Nelson,Wei Pei,Shanshan Yan,Bao‐Ngoc Nguyen,Timothy Hoffman,Barun Okram,Truc N. Nguyen,Songchun Jiang,Brian T. Masick
标识
DOI:10.1021/acs.jmedchem.6c00127
摘要
Abstract The RAS Switch-II pockets’ discovery enabled targeting a challenging molecular site. Covalent KRASG12C inhibitors inspired efforts to find compounds for other KRAS mutations, notably KRASG12D and KRASG12V. A macrocyclization strategy led to the identification of an exceptionally potent lead compound 12. Highly optimized interactions in the pocket yielded strong affinity against KRASG12D and KRASG12V, potent inhibition of phospho-ERK in various KRAS mutant cell lines, and tumor regression in mouse xenograft models.
科研通智能强力驱动
Strongly Powered by AbleSci AI